Efficacy and Safety of Risankizumab Compared with Apremilast in Patients with Moderate Plaque Psoriasis: Mean PASI and BSA Results From the Phase 4 IMMpulse Trial. (2023). SKIN The Journal of Cutaneous Medicine, 7(6), s257. https://doi.org/10.25251/skin.7.supp.257